Sign In
Buy APRE
$0.762
-0.0022 (-0.288%)
At Close: Jun 03, 2026
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08:30am, Monday, 12'th Aug 2024
Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 – no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
08:30am, Monday, 17'th Jun 2024
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial h
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
08:30am, Tuesday, 14'th May 2024
U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
04:01pm, Monday, 13'th May 2024
DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology t
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.
09:15am, Thursday, 02'nd May 2024
New role enhances company's strong leadership team and solidifies commitment to ongoing clinical innovation New role enhances company's strong leadership team and solidifies commitment to ongoing clin
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
07:45am, Tuesday, 26'th Mar 2024
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024
Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
07:48am, Thursday, 14'th Mar 2024
STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company's IND application
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
08:30am, Monday, 11'th Mar 2024
Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors
Company plans to initiate Phase 1 ACESOT-1051 ( A Multi- C enter E valuation of WEE1 Inhibitor in Patients with Advanced So lid T umors, APR- 1051 ) clinical trial evaluating, highly selective, oral W
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
04:45pm, Tuesday, 05'th Mar 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) Four Poster Presentations, Including Posters on ATRN-119
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
08:01am, Tuesday, 06'th Feb 2024
DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
08:00am, Tuesday, 30'th Jan 2024
DOYLESTOWN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology
